NVS - Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease | Benzinga

Novartis AG (NYSE: NVS) announced topline results from the six-month, double-blind period of the Phase 3 APPEAR-C3G study of iptacopan for C3 glomerulopathy (C3G), a group of related conditions that cause the kidneys to malfunction.

Approximately 50% of C3G patients progress to kidney failure within ten years of diagnosis. Each year, approximately 1-2 people per million worldwide are newly diagnosed with C3G.

Last week, the FDA approved iptacopan, under the brand name Fabhalta, as the first oral monotherapy for a rare blood disorder, Full story available on Benzinga.com